Cyclerion Therapeutics, Inc. KRSA
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Each USD of equity lost 39 cents this year.
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 | −0.1 | −0.1 | −0.1 |
| EBITDA $B | · | · | · | · | · | · | · | · |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 | −0.1 | −0.1 | −0.1 |
| Free cash flow $B | · | · | · | −0.0 | −0.0 | −0.1 | −0.1 | −0.1 |
| EPS, diluted $ | −1.11 | −1.21 | −2.25 | −20.28 | −1.32 | −2.56 | −4.49 | −4.21 |
| Dividend / sh $ | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · |
| ROE % | −39.3 | −30.4 | −48.4 | −150.2 | −95.9 | −99.0 | −281.9 | · |
| Shares out B | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.03 | 0.03 | 0.00 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Reconciled in 8 of 19 fiscal years. 22 checks were skipped: the balance sheet is not tagged before 2018. 11 checks were skipped: EPS is not tagged before 2018.